Emergent Medical Partners is a California-based life sciences investment firm focused on medical device and healthcare companies. The firm was founded in 2006 and is headquartered in Portola Valley, California, United States.

Emergent Medical Partners

HealthCor Partners Management, L.P. (''HealthCor Partners''), is a registered investment advisor with the U.S. Securities and Exchange Commission (the “SEC”). Together with its affiliate, HealthCor Partners has approximately $365 million of capital commitments dedicated to private equity investments. HealthCor Partners invests primarily in growth equity and later stage developmental companies across all sectors of the healthcare and life sciences industry.

HealthCor Partners

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the past thirty-plus years of the firm's existence.  Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

U.S. Venture Partners

Capricorn Investment Group was created in 2000 to demonstrate the promise that it is possible to invest profitably while driving sustainable positive change.  Today Capricorn manages the assets for Jeff Skoll, the Skoll Foundation, and others who strive for extraordinary investment results by leveraging market forces to accelerate large-scale impact.  The firm invests in the public equity, fixed income, private equity, and real assets markets across the globe.  Capricorn has offices in Palo Alto, California, and New York, New York.

Capricorn Investment Group

Lifeforce Capital invests in digital health companies enabling new care delivery models or more efficient therapeutic development. Lifeforce Capital is headquartered in San Francisco, California.

Lifeforce Capital

Panorama is a growth private equity firm based in Omaha, with professionals in Palo Alto, Denver, and NYC, having deep roots in Mid-America and Silicon Valley. Over $125M in committed capital from leading family offices, foundations, and entrepreneurs worldwide in Panorama Point Partnership, LP (Fund I), and Co-Investments. Panorama is raising its second investment fund, Panorama Growth Partners, LP (Fund II) – targeting $200M.   Founded on 25 years of investment experience by Stephen J. George, who was previously the Co-Founder and CIO of Capricorn Investment Group, a $5B private investment firm; and Clarey L. Castner, the former CEO of the University of Nebraska Foundation.  Commenced operations in 2013 with the mission to be the most dynamic and rewarding private equity partnership worldwide. At the core of Panorama’s investment philosophy is to invest in compelling, hard-to-access diversified growth-stage companies across the risk-reward spectrum.

Panorama Point Partners

Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span equity, fixed income, currency, commodity, and alternative markets. They also offer asset allocation, multi-manager, and speciality approaches.

Wellington Management

Baillie Gifford is an independently owned investment management firm. It is owned and run by 39 of its senior executives, who operate as a partnership, a structure that has endured for over a century and provides stability for clients and motivation for employees. It enables them to manage the business for the future as well as the present, with an emphasis on genuine long-term thinking rather than lurching haplessly between short-term targets.

Baillie Gifford

Cube is the family office founded by the Rancilio family in 2013, after the sale of the espresso machine company founded in 1927 by our grandfather Roberto. The Rancilio family managed its company for three generations, during the course of which it became a leading global espresso producer. After selling the family business, we created Rancilio Cube. Cube focuses on venture, growth and impact investments, and makes both direct and fund investments. With regard to direct investments, we invested in companies such as Lyft (made in 2015, we consider it as our ''cornerstone'' venture/growth investment), Sennder, N26, SpaceX, Airbnb, Wise, 23andme, Uber, Flexport, Deliveroo, SumUp, Capsule, Coursera, Lyst, Omaze, Prodigy Finance, Taboola, Applause, Reef, Rapyd, Logz.io, Tier, Toast, Bnext, Treedom, Casavo and many more.  Cube also makes limited partner investments in international VC funds: examples include Pelion, Earlybird DE, Cherry Venture, Foundation Capital, Khosla, NEA, Lake Star, Hoxton Venture, Hetz, Glilot, Cavalry, Bessemer, Omega, Blue Lion, TCV, Firstmark, Seedcamp, Holtzbrinck, OWL, Better Tomorrow, Zetta, DST, Jackson Square Venture, GSquared, Speedinvest, Target GlobaI, Aspect Ventures, Oxford Science Innovation, Triodos Organic Growth and other funds. From 2022 we are a fully compliant investment company for professional investors. We got an embedded global network, with a particularly deep and wide set of relationships in the Us/European investment and corporate markets. Cube goes out of its way to open up its networks for the benefit of the companies and funds in which it has invested.

Rancilio Cube Sicaf

Martis Capital is a middle-market private equity fund focused exclusively on the North American healthcare industry.

Martis Capital

Hayfin was founded in 2009 with the ambition of creating one of Europe’s leading investment platforms. They focus on delivering best-in-class risk-adjusted returns for their investors across four strategies: Direct Lending, Special Opportunities, High-Yield Credit and Securitized Credit. Hayfin is a London based firm with offices in Amsterdam, Frankfurt, Mardid, Paris and Luxembourg. They consider their selves value investors, generating differentiated return through hard work, insightful analysis and disciplined investing. Hayfin seeks to recruit and retain exceptionally talented professionals. They believe in being local in each of their markets, and that their diverse mix of nationalities, cultures and languages makes them more connected to these markets. Most of their team are industry generalists, with their edge lying in their origination networks and proven expertise in managing complex restructurings, workouts and liquidations. That said, they employ dedicated, specialist teams in the areas of healthcare (life sciences), shipping (maritime) and real estate, where they believe their focused expertise provides an advantage. They operate across all major European geographies with offices in London, Paris, Madrid, Frankfurt, Luxembourg and Tel Aviv, and have a growing presence in the United States with an office in New York.

Hayfin Capital Management

Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value.

Bain Capital Life Sciences

Janus Henderson Group plc is a global asset management group. Janus Henderson Investors exists to help clients achieve their long-term financial goals. We currently manage £265.3bn (US$371.9bn) and employ more than 2000 members of staff worldwide (as at 31 March 2018).

Janus Henderson Investors

HeartFlow

HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.

<div><p>HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow&rsquo;s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow&rsquo;s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.</p></div>

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

<div>
  <p>
    HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow&rsquo;s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow&rsquo;s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.
  </p>
</div>


<div>
  <p>
    CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.
  </p>
</div>


CMRSurgical

<div>
  <p>
    Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.
  </p>
</div>


Imperative Care

<div>
  <p>
    Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science&reg;. The GentleWave&reg; System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO&reg; Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
  </p>
</div>


Sonendo

<div>
  <p>
    Sientra is a medical device company that offers breast implant treatments for breast augmentation and reconstruction. The company is based in Santa Barbara, California.  Sientra is committed to providing plastic surgeons with intuitive, elegant solutions&mdash;as reflected in its innovative round and shaped product lines. It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.
    
    Sientra was founded by Hani Zeini in
  </p>
</div>


Sientra

<div>
  <p>
    Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes.
    
    The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
  </p>
</div>


Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring).

HeartFlow

Next-gen Medical Devices

Key stats

EDGE Insights

Digital Health (Q2 2023): Funding flow steady; first AI-drug enters Phase II clinical trials

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless